Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study

• Published in: Pharmaceutics 2023-09, Vol.15 (9), p.2357
• Main Authors: Kim, Gwanyoung, Moon, Hyun-ki, Kim, Taeheon, Yun, So-hye, Yun, Hwi-yeol, Hong, Jang Hee, Kim, Dae-Duk
• Format: Article
• Language: English
• Subjects: Acids; Acquired immune deficiency syndrome; AIDS; Blood; camostat mesylate; Clinical trials; COVID-19; Drug dosages; Electrocardiography; Ethylenediaminetetraacetic acid; GBA; GBPA; Health aspects; HIV; Human immunodeficiency virus; Internal medicine; Medical laboratories; Medical research; Medicine, Experimental; Metabolites; modeling; Pharmaceutical industry; Pharmacokinetics; Plasma; population pharmacokinetics; Regression analysis; RNA polymerase; Severe acute respiratory syndrome coronavirus 2; simulation; Vaccines; Vital signs
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15092357

Camostat mesylate is expected to be promising as a treatment option for COVID-19, in addition to other indications for which it is currently used. Furthermore, in vitro experiments have confirmed the potential of camostat and its metabolites to be effective against COVID-19. Therefore, clinical trials were conducted to evaluate the safety and pharmacokinetic characteristics of camostat after single-dose administration. Additionally, we aim to predict the pharmacokinetics of repeated dosing through modeling and simulation based on clinical trials. Clinical trials were conducted on healthy Korean adults, and an analysis was carried out of the metabolites of camostat, GBPA, and GBA. Pharmacokinetic modeling and simulation were performed using Monolix. There were no safety issues (AEs, physical examinations, clinical laboratory tests, vital sign measurements, and ECG) during the clinical trial. The pharmacokinetic characteristics at various doses were identified. It was confirmed that AUC last and Cmax increased in proportion to dose in both GBPA and GBA, and linearity was also confirmed in log-transformed power model regression. Additionally, the accumulation index was predicted (1.12 and 1.08 for GBPA and GBA). The pharmacokinetics of camostat for various dose administrations and indications can be predicted prior to clinical trials using the developed camostat model. Furthermore, it can be used for various indications by connecting it with pharmacodynamic information.